10:11 AM
 | 
Apr 14, 2017
 |  BC Week In Review  |  Company News  |  Deals

BMS, Roche deal

Bristol-Myers granted Roche rights to BMS-986089, a fusion protein designed to suppress myostatin (MSTN; GDF8). According to...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >